Conatus Pharmaceuticals, Inc.
(NASDAQ : CNAT)

( )
CNAT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.48%171.281.3%$490.30m
BIIBBiogen Inc.
-0.90%227.061.3%$435.96m
CELGCelgene Corporation
-0.41%95.241.3%$435.38m
GILDGilead Sciences, Inc.
-0.42%66.890.9%$421.14m
ILMNIllumina, Inc.
1.13%312.453.5%$304.49m
REGNRegeneron Pharmaceuticals, Inc.
-0.86%312.562.6%$284.79m
AAgilent Technologies, Inc.
0.99%68.371.6%$218.10m
VRTXVertex Pharmaceuticals Incorporated
-0.72%171.771.9%$178.12m
EXASExact Sciences Corporation
3.06%96.8825.3%$165.46m
ALXNAlexion Pharmaceuticals, Inc.
1.45%127.152.0%$148.25m
BMRNBioMarin Pharmaceutical Inc.
2.42%89.074.3%$119.32m
INCYIncyte Corporation
1.55%81.752.5%$110.60m
SRPTSarepta Therapeutics, Inc.
2.19%120.8414.7%$106.75m
ALNYAlnylam Pharmaceuticals, Inc
1.50%68.939.2%$99.72m
IONSIonis Pharmaceuticals, Inc.
-3.60%64.728.2%$96.34m

Company Profile

Conatus Pharmaceuticals, Inc. is a biotechnology company, which engages in the development and commercialization of medicines for the treatment of liver diseases. It focuses in development of emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.